NEW YORK (GenomeWeb) – Akesogen, a contract research organization that specializes in personalized medicine, has received accreditation for its oncology testing services from the College of American Pathologists.
"This is an important endorsement by the College of American Pathologists for Akesogen to provide our comprehensive cytogenomics oncology tests and services for a wide spectrum of solid and liquid tumors," Gabriela Oprea, director of the firm's Atlanta-based testing facility, said in a statement. She added that the tests are offered as a complement to next-generation sequencing-based clinical oncology testing.
The CAP Laboratory Accreditation Program involves a process of inspections of clinical lab records and quality control procedures, assessments of a lab's staff qualifications, equipment, facilities, safety program, and overall management.
Akesogen offers genomic, genetic, and bio-banking services for clinical trials, clinical diagnostic testing, and research. Its offerings include high-throughput biomarker profiling, cytogenetic arrays, sequencing, and genomics analyses of nucleic acids and epigenetic markers.
In September 2015, Akesogen launched a co-marketing agreement with BioDiscovery to provide end-to-end solutions for cytogenomic array and next-generation sequencing services.